The SmallCap Network released a promotional PR on Pharmacyte Biotech Inc (OTCMKTS:PMCB) highlighting the Cell-in-a-Box Technology of the company. It stated that while many biotech firms are developing new oncology drugs, what’s often unacknowledged about cancer therapy is how a small change in the way drugs are administered can make a huge difference in their effectiveness.
Pharmacyte understands this difference and has embraced the advantage of improved dosing measures. It had formulated a method that could transform the way everyone thinks about pharmaceuticals. The SmallCap Network talked about Cell-in-a-Box® technology.
As the technology name suggests, it is a means to encapsulate a different living cells in a tiny container that can be deposited in an area of the body to get a therapeutic benefit. These are hardly the size of the pin’s head and can be surgically deposited within the body.
The potential of such an approach is virtually endless, though Pharmacyte has disclosed that it will first focus on formulating the technology as a way of administering a drug called ifosfamide to combat pancreatic cancer.
Ifosfamide is known as an effective medication for pancreatic cancer patients. However, it also results in adverse side effects. For that reason, oncologists prefer combination treatment of Abraxane®, from Celgene Corporation (NASDAQ:CELG), with gemcitabine drug, from Eli Lilly and Co (NYSE:LLY) to treat the fatal disease.
The other preferred therapy is Gemcitabine administered in combination with Tarceva, developed by Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) subsidiary firm Genentech. PharmaCyte’s Cell-in-a-Box technology could bring the difference not only in segment of cancer medications, but of all medicine.
In last trading session, the stock price of gained more than 6% to close the trading session at $0.109.The gains came at a share volume of 1.74 million compared to average share volume of 2.55 million. The market cap stands at $77.08 million.